Standard BioTools Inc

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Standard BioTools Inc posts strong Q4 results, targets margin improvement

Standard BioTools Inc delivered solid Q4 results with revenue growth and cost reductions. The outlook for 2023 includes flat to moderately higher core revenue, improved margins, and strategic expense management. Challenges in genomics and significant operating expenses require attention for sustained growth.

Standard BioTools Inc reports solid Q1 performance and eyes sustained growth

Standard BioTools Inc's Q1 2023 earnings call highlighted positive financial results, operational improvements, and strategic initiatives aimed at driving profitability. While facing challenges in certain revenue segments, the company's focus on cost reduction and revenue growth positions it well for future success.

Standard BioTools Inc. reports robust Q2 earnings, eyes growth opportunities

Standard BioTools Inc. delivered strong financial results in Q2 2023, with revenue growth and improved margins. The company's strategic priorities include stabilizing the core business, enhancing operating discipline, and leveraging M&A for growth. While challenges exist in managing profitability across segments, opportunities for growth through new products and strategic acquisitions are promising.

Standard BioTools Inc (LAB) reports strong Q3 earnings and advances merger with SomaLogic

Standard BioTools Inc (LAB) delivered robust financial results in Q3 2023, showcasing revenue growth, margin expansion, and operational improvements, setting a positive trajectory for future performance.
The company's strategic initiatives, including the pending merger with SomaLogic, signal a commitment to driving growth, fostering innovation, and enhancing shareholder value in a competitive market landscape.
While facing challenges in margin targets and post-merger integration, Standard BioTools Inc (LAB) remains well-positioned to capitalize on opportunities in biotechnology, expand market reach, and sustain its growth momentum.

Standard BioTools Inc (LAB) posts robust Q4 earnings and outlines growth strategies for 2024

Standard BioTools Inc (LAB) delivered a strong performance in Q4 2023, driven by revenue growth, margin expansion, and cost reduction.
The company's strategic focus on profitability, diversified revenue streams, and operational efficiency sets a solid foundation for future growth.
While facing challenges in cost synergies and margin maintenance, Standard BioTools Inc (LAB) is well-positioned to capitalize on opportunities for revenue growth and operational improvements.

Standard BioTools Inc achieves revenue growth and profitability in Q1

Standard BioTools Inc's Q1 2024 performance reflects steady revenue growth and improved profitability. The company's strategic initiatives and strong financial position with $464 million in cash equivalents provide a solid foundation for future growth and value creation.

Standard BioTools Inc accelerates cost reduction efforts amidst revenue challenges

Standard BioTools Inc's Q2 2024 performance focused on cost reduction, revised revenue guidance, and strategic partnerships for future growth.
The company aims to achieve breakeven adjusted EBITDA by 2026, supported by strong cash position and diversified revenue streams.
Challenges include contract delays in SomaScan services and suspension of share repurchase program, while opportunities lie in strategic M&A and new partnerships.
Overall, Standard BioTools Inc navigates market uncertainties with a focus on financial sustainability and operational efficiency for long-term success.

Standard BioTools Inc reports mixed Q3 results, focuses on growth

Standard BioTools Inc's Q3 performance reflects a mixed revenue picture with strong growth in Consumables but a decline in Instruments business. The company's focus on cost management and strategic initiatives to drive long-term growth and profitability is evident.
Maintaining a robust cash position and emphasizing high-margin consumables position Standard BioTools Inc well for future success. Addressing challenges in the Instruments segment and sustaining cost management are key priorities for the company moving forward.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SomaLogic

NEW YORK , Oct. 4, 2023 /PRNewswire/ -- Shareholder rights law firm Julie & Holleman LLP is investigating potential breaches of fiduciary duty relating to the proposed merger between Standard BioTools Inc. (Nasdaq: LAB) and SomaLogic, Inc. (Nasdaq: SLGC). For a no-cost consult and to learn more about our investigation, please click here or visit: https://julieholleman.com/?p=3147 Standard BioTools, previously known as Fluidigm Corporation, is a company that develops, manufactures, and sells technologies that help biomedical researchers develop medicines faster and better.

LAB INVESTOR ALERT: Julie & Holleman LLP Announces Investigation of Proposed Merger Between Standard BioTools and SomaLogic

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. is fair to Standard BioTools shareholders. Under the terms of the agreement, SomaLogic shareholders will receive 1.11 shares of Standard BioTools common stock for each share of SomaLogic common stock owned. Upon closing of the proposed transaction, Standard BioTools shareholders will own approximately 43% of the combined compan.

LAB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Standard BioTools Inc. Is Fair to Shareholders

SomaLogic Inc.'s SLGC, -2.54% stock was up about 12% in premarket trades on Wednesday after the Boulder, Colo.-based specialist in cell proteins agreed to be acquired in an all-stock merger with Standard BioTools LAB, -1.10% valued at about $1 billion.

SomaLogic's stock surges as it agrees to be bought by Standard BioTools in all-stock merger

Activates Standard BioTools' strategy to unlock value in underserved portion of $100 billion industry Establishes leading platform of multi-omic technologies with the highest throughput and highest data quality to power clinical research insights Expands commercial reach with substantial cross-selling opportunities and complementary offerings Generates estimated $80 million of annual cost synergies by 2026 and enhanced combined path to profitability 1 Estimated combined cash of over $500 million at close 2 creates industry-leading balance sheet to fund growth initiatives Standard BioTools increases full year 2023 revenue guidance to $100 - $105 million; SomaLogic reaffirms full year 2023 revenue guidance of $80 - $84 million SOUTH SAN FRANCISCO, Calif. and BOULDER, Colo.

Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools

Continued operational execution improves revenue growth, margin expansion, and expense reduction Continued operational execution improves revenue growth, margin expansion, and expense reduction

Standard BioTools Reports Second Quarter 2023 Financial Results

SOUTH SAN FRANCISCO, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report second quarter 2023 financial results on Tuesday, August 8, 2023, after the close of the market.

Standard BioTools Announces Conference Call and Webcast for Second Quarter 2023 Financial Results

SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm, PhD, will give a presentation at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 9:00 a.m. ET.

Standard BioTools to Present at the Jefferies Healthcare Conference

Altus Power

Ginkgo Bioworks Holdings

Marqeta

Movella Holdings Inc

FiscalNote Holdings Inc

Porch Group

If you're curious about penny stocks, they offer an interesting niche. Whether you're new to trading these stocks or expanding your investment style, understanding what to look for and how to build a strong watch list is obviously important.

7 Top Penny Stocks To Buy According To Insiders In May 2023

Supporting discovery through screening, the X9 is the only system integrating real-time PCR and NGS library preparation Supporting discovery through screening, the X9 is the only system integrating real-time PCR and NGS library preparation

Standard BioTools Announces NGS Library Preparation as an Upgrade on the X9 High-Throughput Genomics System

Industry veteran Jeffrey Black brings 30 years of financial and operating leadership experience Vikram Jog to become Special Advisor for transition period SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced the appointment of Jeffrey Black as Senior Vice President and Chief Financial Officer effective today.

Standard BioTools Appoints Jeffrey Black as Chief Financial Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Standard BioTools Inc. (NASDAQ:LAB ) Q1 2023 Earnings Conference Call May 9, 2023 5:00 PM ET Company Participants Peter DeNardo - Investor Relations Michael Egholm - President and Chief Executive Officer Vikram Jog - Chief Financial Officer Conference Call Participants Operator Hello, and welcome to the Standard BioTools Incoporated First Quarter 2023 Financial Results Conference Call. As a reminder, this conference is being recorded.

Standard BioTools Inc. (LAB) Q1 2023 Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report first quarter 2023 financial results on Tuesday, May 9, 2023, after the close of the market.

Standard BioTools Announces Conference Call and Webcast for First Quarter 2023 Financial Results

SOUTH SAN FRANCISCO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards, effective as of April 20, 2023, under the Standard BioTools Inc. 2022 Inducement Equity Incentive Plan (Inducement Plan), as a material inducement to four individuals entering into employment with Standard BioTools. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced the launch of its newest imaging technology, the Hyperion XTi™ Imaging System, during the American Association for Cancer Research (AACR) meeting in Orlando.

Standard BioTools introduces the Hyperion XTi Imaging System, breaks barriers to power significant advancement in spatial biology

Experienced Life Science Operating Leader Joins Board as Company Enters New Phase Experienced Life Science Operating Leader Joins Board as Company Enters New Phase

Standard BioTools Announces Appointment of Fenel Eloi to Board of Directors

SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm, PhD, will participate in a fireside chat at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023, at 3:00 p.m. ET.

Standard BioTools to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm, PhD, will present at the Cowen Health Care Conference on Wednesday, March 8, 2023, at 12:50 p.m. ET.

Standard BioTools to Present at 43rd Annual Cowen Health Care Conference

Standard BioTools Inc. (NASDAQ:LAB ) Q4 2022 Earnings Conference Call February 14, 2023 5:00 PM ET Company Participants Peter DeNardo - IR Michael Egholm - CEO and President Vikram Jog - CFO Conference Call Participants Operator Hello, and welcome to the Standard BioTools Inc. Fourth Quarter and Full Year 2022 Financial Results Conference Call. As a reminder, this conference is being recorded.

Standard BioTools Inc. (LAB) Q4 2022 Earnings Call Transcript

Fourth quarter 2022 GAAP revenues of $27.0 million; Core product and service revenues of $26.8 million, representing 8.3% sequential growth; Full year GAAP revenues of $97.9 million and core product and service revenues of $94.5 million

Standard BioTools Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Business Outlook

SOUTH SAN FRANCISCO, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report fourth quarter and full year 2022 financial results on Tuesday, February 14, 2023, after the close of the market.

Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2022 Financial Results

Continued commercial and strategic execution delivers sequential core revenue growth of 4%–9% to $26 million–$27 million in Q4 2022 for full year total of approximately $94 million–$95 million

Standard BioTools Provides Preliminary Fourth Quarter 2022 Revenue and Business Update

Former Danaher Executive Further Strengthens Senior Management Team Former Danaher Executive Further Strengthens Senior Management Team

Standard BioTools Announces Appointment of Betsy Jensen as Chief Human Resources Officer

SOUTH SAN FRANCISCO, Calif., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced that its board of directors has authorized the repurchase of up to $20 million of shares of its common stock in the open market or in negotiated transactions through December 31, 2023. The repurchases are expected to be made from cash on hand, which the Company's board believes is an effective use of capital given Standard BioTools' current valuation and progress to date against its stated strategic goals, which are expected to result in improved revenue growth and profitability over time. The repurchase program may be suspended or discontinued at any time at the Company's discretion.

Standard BioTools Authorizes up to $20 Million of Share Repurchases

Standard BioTools Inc. (NASDAQ:LAB ) Q3 2022 Results Conference Call November 8, 2022 5:00 PM ET Company Participants Peter DeNardo - Investor Relations Michael Egholm - Chief Executive Officer and President Vikram Jog - Chief Financial Officer Operator Hello, and welcome to the Standard BioTools Inc. Third Quarter 2022 Financial Results Conference Call. As a reminder, this conference is being recorded.

Standard BioTools Inc. (LAB) Q3 2022 Earnings Call Transcript

Third quarter core product and services revenue increase of 30% sequentially to $24.8 million

News for Standard BioTools Inc Stock (LAB)